Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging

(2018) Suzanne E. Schindler et al.   Alzheimers & Dementia

Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment

(2018) Inês Baldeiras et al.   Alzheimers Research & Therapy

Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale

(2018) Sylvain Lehmann et al.   Frontiers in Aging Neuroscience

Decreased sAβPPβ, Aβ38, and Aβ40 Cerebrospinal Fluid Levels in Frontotemporal Dementia

(2018) Audrey Gabelle et al.   JOURNAL OF ALZHEIMERS DISEASE

Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes

(2018) Armand Perret-Liaudet et al.   JOURNAL OF ALZHEIMERS DISEASE

Performance of Aβ1-40, Aβ1-42, Total Tau, and Phosphorylated Tau as Predictors of Dementia in a Cohort of Patients with Mild Cognitive Impairment

(2018) Lucilla Parnetti et al.   JOURNAL OF ALZHEIMERS DISEASE

Cerebrospinal Fluid Aβ1-40 Improves Differential Dementia Diagnosis in Patients with Intermediate P-tau181P Levels

(2018) Sylvie Slaets et al.   JOURNAL OF ALZHEIMERS DISEASE

Additional Use of Aβ42/Aβ40 Ratio with Cerebrospinal Fluid Biomarkers P-Tau and Aβ42 Increases the Level of Evidence of Alzheimer's Disease Pathophysiological Process in Routine Practice

(2018) Mathilde Sauvée et al.   JOURNAL OF ALZHEIMERS DISEASE

Amyloid-β 42/40 Cerebrospinal Fluid Concentration Ratio in the Diagnostics of Alzheimer's Disease: Validation of Two Novel Assays

(2018) Piotr Lewczuk et al.   JOURNAL OF ALZHEIMERS DISEASE

Spreading of Amyloid, Tau, and Microvascular Pathology in Alzheimer's Disease: Findings from Neuropathological and Neuroimaging Studies

(2018) Dietmar Rudolf Thal et al.   JOURNAL OF ALZHEIMERS DISEASE

Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting

(2017) Christelle Gervaise-Henry et al.   JOURNAL OF ALZHEIMERS DISEASE

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

(2017) Piotr Lewczuk et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia

(2017) Lutz Frölich et al.   Alzheimers Research & Therapy

Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment

(2017) Shorena Janelidze et al.   JAMA Neurology

Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years

(2017) Joakim Hertze et al.   JOURNAL OF ALZHEIMERS DISEASE

Do we still need positron emission tomography for early Alzheimer’s disease diagnosis?

(2016) Piotr Lewczuk et al.   BRAIN

Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study

(2016) Antoine Leuzy et al.   BRAIN

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes

(2016) Hugo Marcel Johan Vanderstichele et al.   JOURNAL OF ALZHEIMERS DISEASE

Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer’s Disease and Dementia with Lewy Bodies

(2016) Olivier Bousiges et al.   JOURNAL OF ALZHEIMERS DISEASE

Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease

(2016) Piotr Lewczuk et al.   JOURNAL OF ALZHEIMERS DISEASE

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

(2016) Shorena Janelidze et al.   Annals of Clinical and Translational Neurology

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET

(2016) Danielle van Westen et al.   Scientific Reports

Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability

(2015) Anthony Fourier et al.   CLINICA CHIMICA ACTA

Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid

(2015) N. Le Bastard et al.   CLINICAL CHEMISTRY

Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease

(2015) Inês Baldeiras et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

(2015) Julien Dumurgier et al.   Alzheimers Research & Therapy

Chasing the Effects of Pre-Analytical Confounders – A Multicenter Study on CSF-AD Biomarkers

(2015) Maria João Leitão et al.   Frontiers in Neurology

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease

(2015) Aline Dorey et al.   Frontiers in Neurology

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

(2014) Niklas Mattsson et al.   BRAIN

CSF biomarker variability in the Alzheimer's Association quality control program

(2013) Niklas Mattsson et al.   Alzheimers & Dementia

Evaluation of the Cerebrospinal Fluid Amyloid-�1-42/Amyloid-�1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders

(2013) Magdalena Nutu et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update

(2012) Marta del Campo et al.   Biomarkers in Medicine

Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer’s disease

(2012) Anne M Fagan et al.   Biomarkers in Medicine

CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings

(2012) T. T. Seppala et al.   NEUROLOGY

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Association Between In Vivo Fluorine 18–Labeled Flutemetamol Amyloid Positron Emission Tomography Imaging and In Vivo Cerebral Cortical Histopathology

(2011) David A. Wolk   ARCHIVES OF NEUROLOGY

Neurochemical dementia diagnostics in Alzheimer’s disease: where are we now and where are we going?

(2011) Piotr Lewczuk et al.   Expert Review of Proteomics

The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia

(2010) P.E. Spies et al.   Current Alzheimer Research

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers

(2009) Piotr Lewczuk et al.   JOURNAL OF NEURAL TRANSMISSION

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

(2009) N A Verwey et al.   ANNALS OF CLINICAL BIOCHEMISTRY

Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease

(2007) Harald Hampel et al.   Alzheimers & Dementia